ALKBH5 Promotes Hepatic Gluconeogenesis via m6A-mediated Stabilization of Ogt mRNA

This study reveals that the glucocorticoid-responsive demethylase ALKBH5 promotes hepatic gluconeogenesis and type 2 diabetes by stabilizing Ogt mRNA through m6A demethylation, identifying ALKBH5 as a promising therapeutic target for the disease.

The Gist

The Big Picture: The Liver's "Sugar Factory"

Imagine your liver is a sugar factory. When you haven't eaten for a while (like when you are sleeping or fasting), this factory needs to switch on its machines to produce sugar (glucose) and pump it into your bloodstream to keep your brain and muscles running. This process is called gluconeogenesis.

In people with Type 2 Diabetes, this factory gets stuck in "overdrive." It keeps pumping out too much sugar even when you don't need it, leading to dangerously high blood sugar levels.

The New Discovery: A "Post-It Note" System

For a long time, scientists thought the factory was controlled only by the "bosses" (hormones) shouting orders to turn the machines on. But this paper discovered a new layer of control: a post-it note system attached to the factory's instruction manuals (RNA).

• The Instruction Manual (mRNA): This is the blueprint the factory uses to build sugar-making machines.
• The Post-it Note (m6A): This is a tiny chemical tag stuck onto the blueprint.
  • If the tag is there, the blueprint gets shredded quickly (the machine isn't built).
  • If the tag is removed, the blueprint stays safe and gets used to build many machines.

The Main Character: ALKBH5 (The "Eraser")

The star of this story is a protein called ALKBH5. Think of ALKBH5 as a specialized eraser.

1. The Trigger: When your body is stressed or fasting, a hormone called Cortisol (the "stress hormone") arrives at the liver.
2. The Activation: Cortisol tells the liver to make more of the eraser (ALKBH5).
3. The Action: The eraser goes to the instruction manual for a specific protein called OGT. It erases the "shred me" post-it note.
4. The Result: Because the note is gone, the OGT manual survives longer. The factory builds more OGT.
5. The Chain Reaction: More OGT means the factory ramps up its sugar production, releasing more glucose into your blood.

In short: Stress hormone $\rightarrow$ More Eraser (ALKBH5) $\rightarrow$ More OGT $\rightarrow$ Too much Sugar.

The Experiment: What Happened When They Stopped the Eraser?

The researchers wanted to see if they could stop this runaway sugar factory. They did two things:

1. Genetic Test: They took mice and removed the gene that makes the eraser (ALKBH5).

   • Result: Without the eraser, the "shred me" notes stayed on the OGT manuals. The OGT levels dropped, and the sugar factory slowed down. The mice had better blood sugar control.

2. Drug Test: They used a new drug (called 18l) that acts like a glove for the eraser. It stops the eraser from working.

   • Result: When they gave this drug to diabetic mice (both normal and obese "db/db" mice), the sugar factory calmed down. The mice's blood sugar levels improved, and they handled glucose much better, without any obvious side effects.

Why This Matters

This paper is a breakthrough for a few reasons:

• It's a New Switch: We knew hormones controlled sugar, but we didn't know this specific "post-it note" system was the bridge between the hormone and the sugar production.
• A New Treatment: Currently, diabetes drugs often try to block the sugar machines directly, which can be tricky. This study suggests we could instead block the eraser (ALKBH5). If we stop the eraser, the sugar production naturally slows down.
• Hope for the Future: The drug they tested (18l) worked well in mice. While it needs more testing before it can be used in humans, it proves that targeting this "eraser" is a promising new way to treat Type 2 Diabetes.

Summary Analogy

Imagine a library where books (instructions) are being thrown into a shredder (degradation).

• ALKBH5 is the librarian who pulls the "shred" tags off the books.
• Cortisol is the manager yelling, "We need more books!"
• The librarian (ALKBH5) listens to the manager, pulls the tags off the OGT book, and suddenly the library is full of OGT books.
• These OGT books tell the factory to make sugar.
• The new drug is like putting the librarian's hands in handcuffs. The librarian can't pull the tags off anymore, the OGT books get shredded, and the sugar factory slows down.

This research opens a door to a new kind of medicine that fixes the "library management" of our cells to cure diabetes.

Technical Summary

1. Problem Statement

Excessive hepatic glucose production (HGP), driven by unrestrained hepatic gluconeogenesis, is a primary cause of fasting hyperglycemia in Type 2 Diabetes Mellitus (T2DM). While transcriptional regulation of gluconeogenic genes is well-characterized, the epitranscriptomic mechanisms (specifically RNA modifications) that sustain this dysregulation in response to hormonal cues remain poorly understood. Specifically, the dynamic interplay between glucocorticoid signaling, RNA N6-methyladenosine (m6A) methylation, and the stability of metabolic transcripts in hepatocytes requires further elucidation to identify novel therapeutic targets for T2DM.

2. Methodology

The study employed a multi-disciplinary approach combining in vitro cell models, in vivo mouse genetics, and high-throughput sequencing:

• Cell Models: Mouse primary hepatocytes (MPH) and AML12 hepatocyte cell lines were treated with Dexamethasone (Dex) and Forskolin (Fsk) to pharmacologically induce gluconeogenesis.
• Genetic Models:
  • Global Alkbh5 knockout (KO) mice.
  • Hepatocyte-specific Alkbh5 conditional knockout (cKO) mice (generated using Alb-Cre).
  • db/db mice (a model of T2DM).
• Omics and Molecular Profiling:
  • m6A-seq: Transcriptome-wide mapping of m6A methylation changes in MPH under gluconeogenic stimulation and in Alkbh5-deficient cells.
  • RIP-seq & RIP-qPCR: RNA Immunoprecipitation to identify direct RNA targets of ALKBH5.
  • ChIP-seq & ChIP-qPCR: Chromatin Immunoprecipitation to verify Glucocorticoid Receptor (GR) binding to the Alkbh5 promoter.
  • ATAC-seq Analysis: Used to assess chromatin accessibility at the Alkbh5 locus.
  • RNA Stability Assays: Actinomycin D chase experiments to measure mRNA half-life.
  • Polysome Profiling: To assess translation efficiency.
• Pharmacological Intervention: Treatment with 18l, a covalent small-molecule inhibitor of ALKBH5, in both wild-type and db/db mice to assess therapeutic potential.
• Functional Assays: Glucose output assays, Pyruvate Tolerance Tests (PTT), Glucose Tolerance Tests (GTT), and Western blotting/qPCR for key gluconeogenic enzymes (PCK1, G6PC) and OGT.

3. Key Contributions

• Discovery of a Glucocorticoid-m6A Axis: The study establishes that glucocorticoid signaling directly upregulates the m6A demethylase ALKBH5 via GR binding to its promoter, linking endocrine stress to epitranscriptomic remodeling.
• Identification of OGT as a Direct Target: The authors identified Ogt (O-linked N-acetylglucosamine transferase) mRNA as a primary direct target of ALKBH5. They demonstrated that ALKBH5 removes m6A marks from Ogt mRNA to prevent its degradation.
• Mechanistic Elucidation: The paper defines a specific regulatory axis: GR $\rightarrow$ ALKBH5 $\rightarrow$ Ogt mRNA stabilization $\rightarrow$ OGT protein upregulation $\rightarrow$ Enhanced gluconeogenesis.
• Therapeutic Validation: The study provides in vivo proof-of-concept that pharmacological inhibition of ALKBH5 using compound 18l effectively suppresses hepatic gluconeogenesis and improves glucose tolerance in diabetic models.

4. Key Results

• Gluconeogenic Activation Triggers m6A Remodeling: Treatment of hepatocytes with Dex/Fsk induced a global shift toward hypomethylation (reduced m6A levels), with hypomethylated RNAs enriched in metabolic pathways.
• ALKBH5 is Upregulated by Glucocorticoids:
  • ALKBH5 expression increased significantly in MPH and fasted mouse livers.
  • GR binds directly to a specific cis-regulatory element in the Alkbh5 promoter, driving its transcription.
  • Inhibition of GR (using mifepristone) blocked ALKBH5 induction.
• ALKBH5 Promotes Gluconeogenesis:
  • Overexpression of ALKBH5 increased PCK1 and G6PC expression and glucose output.
  • Alkbh5 KO (global and hepatocyte-specific) mice exhibited suppressed gluconeogenesis, lower PCK1/G6PC levels, and improved glucose tolerance.
• Mechanism: ALKBH5 Stabilizes Ogt mRNA:
  • m6A-seq and RIP-seq identified Ogt as a top candidate.
  • In the absence of ALKBH5, Ogt mRNA became hypermethylated and its half-life decreased (mediated by the m6A reader YTHDF2).
  • ALKBH5 overexpression stabilized Ogt mRNA, increasing OGT protein levels.
  • Knockdown of Ogt abolished the pro-gluconeogenic effects of ALKBH5 overexpression.
• Pharmacological Inhibition:
  • The ALKBH5 inhibitor 18l reduced OGT, PCK1, and G6PC levels in hepatocytes.
  • In db/db mice, 18l treatment (2 mg/kg) significantly improved glucose tolerance and suppressed hepatic gluconeogenesis without causing toxicity or weight loss.

5. Significance

• Novel Regulatory Layer: This work uncovers a critical post-transcriptional layer of gluconeogenic control, demonstrating that hormonal signals (glucocorticoids) utilize the m6A machinery to fine-tune metabolic output.
• Target Identification: It identifies ALKBH5 as a critical node connecting endocrine stress to metabolic disease and validates OGT as a downstream effector in this pathway.
• Therapeutic Potential: The study highlights ALKBH5 as a promising drug target for T2DM. The successful use of inhibitor 18l in diabetic mouse models suggests that targeting epitranscriptomic regulators could offer a new strategy to treat hyperglycemia, potentially with greater specificity than current therapies.
• Substrate Specificity: The findings contrast with previous studies (e.g., ALKBH5 regulating Gcgr), highlighting the tissue-specific and context-dependent nature of ALKBH5 substrates in metabolic regulation.